| pubmed-article:8241215 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8241215 | lifeskim:mentions | umls-concept:C0019764 | lld:lifeskim |
| pubmed-article:8241215 | lifeskim:mentions | umls-concept:C0021081 | lld:lifeskim |
| pubmed-article:8241215 | lifeskim:mentions | umls-concept:C0199176 | lld:lifeskim |
| pubmed-article:8241215 | lifeskim:mentions | umls-concept:C0340530 | lld:lifeskim |
| pubmed-article:8241215 | lifeskim:mentions | umls-concept:C0681842 | lld:lifeskim |
| pubmed-article:8241215 | lifeskim:mentions | umls-concept:C0679426 | lld:lifeskim |
| pubmed-article:8241215 | lifeskim:mentions | umls-concept:C0332291 | lld:lifeskim |
| pubmed-article:8241215 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:8241215 | pubmed:dateCreated | 1993-12-23 | lld:pubmed |
| pubmed-article:8241215 | pubmed:abstractText | To determine whether immunosuppressive prophylaxis reduces the effect of HLA-DR incompatibility on rejection, we compared clinical and immunologic variables of patients given horse antithymocyte globulin, OKT3, or no immunosuppressive prophylaxis. Median follow-up was 27 months. Groups were similar in race; preoperative HLA reactivity; ABO matching; number of HLA-A, -B, -C, and -DR mismatches; and rejection severity. Patients given immunosuppressive prophylaxis were younger (p = 0.04), had a greater frequency of preoperative ischemic disease (p = 0.03), and had a higher 6-month rejection rate (p = 0.02). A highly significant association was found between the number of mismatches at the HLA-DR locus and rejection severity (p = 0.005). Within the OKT3-based immunosuppressive prophylaxis group and the no immunosuppressive prophylaxis group a significant association was found between the number of HLA-DR mismatches and rejection severity (p = 0.01 and p = 0.009, respectively). A similar trend was identified in the group given horse antithymocyte globulin-based immunosuppressive prophylaxis. Logistic regression, used to identify independent predictors of rejection, showed that the number of HLA-DR mismatches and not the use or type of immunosuppressive prophylaxis is significantly associated with rejection (p = 0.0009). One-year patient survival was 83% in the group with two HLA-DR mismatches and 85% in the group with one or no HLA-DR mismatch. Thus the lower rejection rates in patients with one or no HLA-DR mismatch were not associated with a 1-year survival, which was better than that of patients with two HLA-DR mismatches. The potential benefit of HLA-DR matching on rejection and patient survival must be confirmed by larger prospective studies. | lld:pubmed |
| pubmed-article:8241215 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8241215 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8241215 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8241215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8241215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8241215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8241215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8241215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8241215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8241215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8241215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8241215 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8241215 | pubmed:issn | 1053-2498 | lld:pubmed |
| pubmed-article:8241215 | pubmed:author | pubmed-author:JohnsonMM | lld:pubmed |
| pubmed-article:8241215 | pubmed:author | pubmed-author:RobinsonJJ | lld:pubmed |
| pubmed-article:8241215 | pubmed:author | pubmed-author:RadvanyRR | lld:pubmed |
| pubmed-article:8241215 | pubmed:author | pubmed-author:FisherS GSG | lld:pubmed |
| pubmed-article:8241215 | pubmed:author | pubmed-author:KaoWW | lld:pubmed |
| pubmed-article:8241215 | pubmed:author | pubmed-author:Costanzo-Nord... | lld:pubmed |
| pubmed-article:8241215 | pubmed:author | pubmed-author:O'SullivanE... | lld:pubmed |
| pubmed-article:8241215 | pubmed:author | pubmed-author:MullenG MGM | lld:pubmed |
| pubmed-article:8241215 | pubmed:author | pubmed-author:HerouxAA | lld:pubmed |
| pubmed-article:8241215 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8241215 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:8241215 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8241215 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8241215 | pubmed:pagination | 779-89 | lld:pubmed |
| pubmed-article:8241215 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8241215 | pubmed:meshHeading | pubmed-meshheading:8241215-... | lld:pubmed |
| pubmed-article:8241215 | pubmed:meshHeading | pubmed-meshheading:8241215-... | lld:pubmed |
| pubmed-article:8241215 | pubmed:meshHeading | pubmed-meshheading:8241215-... | lld:pubmed |
| pubmed-article:8241215 | pubmed:meshHeading | pubmed-meshheading:8241215-... | lld:pubmed |
| pubmed-article:8241215 | pubmed:meshHeading | pubmed-meshheading:8241215-... | lld:pubmed |
| pubmed-article:8241215 | pubmed:meshHeading | pubmed-meshheading:8241215-... | lld:pubmed |
| pubmed-article:8241215 | pubmed:meshHeading | pubmed-meshheading:8241215-... | lld:pubmed |
| pubmed-article:8241215 | pubmed:meshHeading | pubmed-meshheading:8241215-... | lld:pubmed |
| pubmed-article:8241215 | pubmed:meshHeading | pubmed-meshheading:8241215-... | lld:pubmed |
| pubmed-article:8241215 | pubmed:meshHeading | pubmed-meshheading:8241215-... | lld:pubmed |
| pubmed-article:8241215 | pubmed:meshHeading | pubmed-meshheading:8241215-... | lld:pubmed |
| pubmed-article:8241215 | pubmed:meshHeading | pubmed-meshheading:8241215-... | lld:pubmed |
| pubmed-article:8241215 | pubmed:meshHeading | pubmed-meshheading:8241215-... | lld:pubmed |
| pubmed-article:8241215 | pubmed:meshHeading | pubmed-meshheading:8241215-... | lld:pubmed |
| pubmed-article:8241215 | pubmed:meshHeading | pubmed-meshheading:8241215-... | lld:pubmed |
| pubmed-article:8241215 | pubmed:meshHeading | pubmed-meshheading:8241215-... | lld:pubmed |
| pubmed-article:8241215 | pubmed:meshHeading | pubmed-meshheading:8241215-... | lld:pubmed |
| pubmed-article:8241215 | pubmed:meshHeading | pubmed-meshheading:8241215-... | lld:pubmed |
| pubmed-article:8241215 | pubmed:meshHeading | pubmed-meshheading:8241215-... | lld:pubmed |
| pubmed-article:8241215 | pubmed:meshHeading | pubmed-meshheading:8241215-... | lld:pubmed |
| pubmed-article:8241215 | pubmed:meshHeading | pubmed-meshheading:8241215-... | lld:pubmed |
| pubmed-article:8241215 | pubmed:meshHeading | pubmed-meshheading:8241215-... | lld:pubmed |
| pubmed-article:8241215 | pubmed:articleTitle | HLA-DR incompatibility predicts heart transplant rejection independent of immunosuppressive prophylaxis. | lld:pubmed |
| pubmed-article:8241215 | pubmed:affiliation | Department of Medicine, Loyola University Chicago, Maywood, Ill. 60153. | lld:pubmed |
| pubmed-article:8241215 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8241215 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8241215 | lld:pubmed |
